GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCure Inc (NAS:NXTC) » Definitions » EV-to-EBIT

NextCure (NextCure) EV-to-EBIT : 0.97 (As of Apr. 27, 2024)


View and export this data going back to 2019. Start your Free Trial

What is NextCure EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, NextCure's Enterprise Value is $-65.70 Mil. NextCure's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-67.64 Mil. Therefore, NextCure's EV-to-EBIT for today is 0.97.

The historical rank and industry rank for NextCure's EV-to-EBIT or its related term are showing as below:

NXTC' s EV-to-EBIT Range Over the Past 10 Years
Min: -52.36   Med: 2.52   Max: 6.08
Current: 0.97

During the past 7 years, the highest EV-to-EBIT of NextCure was 6.08. The lowest was -52.36. And the median was 2.52.

NXTC's EV-to-EBIT is ranked better than
67.04% of 443 companies
in the Biotechnology industry
Industry Median: 8.19 vs NXTC: 0.97

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. NextCure's Enterprise Value for the quarter that ended in Dec. 2023 was $-69.88 Mil. NextCure's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-67.64 Mil. NextCure's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 96.78%.


NextCure EV-to-EBIT Historical Data

The historical data trend for NextCure's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCure EV-to-EBIT Chart

NextCure Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial -32.53 -0.50 0.76 1.50 1.03

NextCure Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.50 1.36 1.01 1.09 1.03

Competitive Comparison of NextCure's EV-to-EBIT

For the Biotechnology subindustry, NextCure's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NextCure's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NextCure's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NextCure's EV-to-EBIT falls into.



NextCure EV-to-EBIT Calculation

NextCure's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-65.699/-67.637
=0.97

NextCure's current Enterprise Value is $-65.70 Mil.
NextCure's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-67.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NextCure  (NAS:NXTC) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

NextCure's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-67.637/-69.88458
=96.78 %

NextCure's Enterprise Value for the quarter that ended in Dec. 2023 was $-69.88 Mil.
NextCure's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-67.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NextCure EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of NextCure's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


NextCure (NextCure) Business Description

Traded in Other Exchanges
Address
9000 Virginia Manor Road, Suite 200, Beltsville, MD, USA, 20705
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include NC410 a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for LAIR-1 and is designed to block immune suppression mediated by LAIR-1, NC762 a monoclonal antibody that binds specifically to human B7 homolog 4 protein, or B7-H4, a protein expressed on multiple tumor types, and NC525 (LAIR-1 mAb) is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia, or AML, blast cells, and leukemic stem cells, or LSCs.
Executives
Anne Elizabeth Borgman director 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Ellen Feigal director C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Kevin G. Shaw officer: Sr VP, Legal Affairs 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Sourav Kundu officer: Sr VP, Dev. & Mfg. 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Han Myint officer: Chief Medical Officer C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Timothy Mayer officer: Chief Operating Officer C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Sol Langermann officer: Chief Scientific Officer C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Steven P. Cobourn officer: Chief Financial Officer C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Linda Liu officer: SVP, Research C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Michael Richman director, officer: President & CEO 2635 TECHNOLOGY FOREST BLVD., HOUSTON TX 77381
John G Houston director C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Garry A Nicholson director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Anand Mehra 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Michael Powell 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
James Healy 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025

NextCure (NextCure) Headlines

From GuruFocus

NextCure to Present at SVB Securities Global Biopharma Conference

By Stock market mentor Stock market mentor 02-07-2023

NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board

By Value_Insider Value_Insider 10-27-2022

NextCure Inc (NXTC) Reports Q3 2023 Financial Results

By GuruFocus Research 11-02-2023